MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

RedHill Biopharma Ltd - Company Profile (NASDAQ:RDHL)

Consensus Ratings for RedHill Biopharma Ltd - (NASDAQ:RDHL) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $29.43 (177.89% upside)

Analysts' Ratings History for RedHill Biopharma Ltd - (NASDAQ:RDHL)
Show:
DateFirmActionRatingPrice TargetActions
5/3/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016NomuraReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/28/2016HC WainwrightReiterated RatingBuy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015Ascendiant Capital MarketsLower Price TargetBuy$28.00 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2015Northland SecuritiesInitiated CoverageBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015MLV & Co.Initiated CoverageBuy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for RedHill Biopharma Ltd - (NASDAQ:RDHL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
4/20/2016Q1($0.48)$0.04ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.51)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2015Q215($0.49)($0.07)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115($0.56)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015Q414($0.60)$0.06ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.61)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/24/2014($0.38)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
6/6/2014($0.44)$0.39ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2014($0.44)$0.39ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3 13($0.62)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for RedHill Biopharma Ltd - (NASDAQ:RDHL)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.49)($0.49)($0.49)
Q2 20161($0.54)($0.54)($0.54)
Q3 20162($0.59)($0.53)($0.56)
Q4 20162($0.63)($0.34)($0.49)
(Data provided by Zacks Investment Research)
Dividend History for RedHill Biopharma Ltd - (NASDAQ:RDHL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for RedHill Biopharma Ltd - (NASDAQ:RDHL)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for RedHill Biopharma Ltd - (NASDAQ:RDHL)
DateHeadline
06/23/16 06:40 PMRedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA(TM) for IBS-D
06/23/16 06:40 PMDGAP-News: RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA(TM) for IBS-D
06/23/16 08:45 AMEquity Research and Technical Review on Redhill Biopharma Ltd. (NASDAQ:RDHL) - Press Telegraph
06/22/16 06:01 PMRedHill Biopharma Announces Publication Demonstrating Potential Efficacy of RHB-104 for Crohn's Disease Associated with MAP Infection
06/22/16 06:01 PMREDHILL BIOPHARMA LTD ADR
06/22/16 06:01 PMRedHill Biopharma (RDHL) Announces YELIVA Phase 1 Met All Primary Objectives in Adv. Solid Tumors
06/22/16 10:48 AMRedHill Biopharma (RDHL) RHB-104 Potential Efficacy Highlighted in Publication - StreetInsider.com
06/22/16 09:11 AMRedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva -
06/21/16 05:37 PMRedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA(TM) in Advanced Solid Tumors
06/21/16 05:37 PMRedHill Meets Goals In Phase 1 Study With YELIVA In Advanced Solid Tumors
06/21/16 10:24 AMRedHill Biopharma (RDHL) Announces YELIVA Phase 1 Met All Primary Objectives in Adv. Solid Tumors - StreetInsider.com
06/21/16 08:24 AMRedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA™ in Advanced Solid Tumors - [GlobeNewswire] - Final results from the Phase I study with YELIVA™ in patients with advanced solid tumors confirmed that the study, conducted at the Medical University of South Carolina, successfully met its primary and ...
06/20/16 07:38 AMRedhill Biopharma Ltd. (RDHL) Analyst Price Targets For The Coming Week - Fiscal Standard
06/20/16 07:00 AMRedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA™ for IBS-D - [GlobeNewswire] - The first patients have been dosed in the randomized, double-blind, placebo-controlled Phase II study with BEKINDA™ 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome in 120 subjects ...
06/15/16 07:00 AMRedHill Biopharma to Present at JMP Securities Life Sciences Conference - [GlobeNewswire] - TEL-AVIV, Israel, June 15, 2016-- RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small ...
06/03/16 08:58 AMShare Rating Focus on Redhill Biopharma Ltd. (NASDAQ:RDHL) - HNN - Share Rating Focus on Redhill Biopharma Ltd. (NASDAQ:RDHL)HNNPresently, Wall Street analysts have given a consensus stock rating of 1.25 on shares of Redhill Biopharma Ltd. (NASDAQ:RDHL). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research. This consensus ...and more »
06/02/16 06:31 PMTarget Price and Stock Performance Rundown for Redhill Biopharma Ltd. (NASDAQ:RDHL) - HNN - Target Price and Stock Performance Rundown for Redhill Biopharma Ltd. (NASDAQ:RDHL)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Redhill Biopharma Ltd. (NASDAQ ...and more »
06/02/16 06:31 PMRedhill Biopharma Ltd. (RDHL) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Redhill Biopharma Ltd. (RDHL) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Redhill Biopharma Ltd. (RDHL). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, ...and more »
06/01/16 06:40 PMAbercrombie & Fitch Co. (NYSE:ANF) decreased -4.56%: RedHill Biopharma Ltd. (NASDAQ:RDHL), Century ... - KC Register - Abercrombie & Fitch Co. (NYSE:ANF) decreased -4.56%: RedHill Biopharma Ltd. (NASDAQ:RDHL), Century ...KC RegisterRedHill Biopharma Ltd. (NASDAQ:RDHL) traded 5006 shares and its share price advanced 0.36% to close at $11.02. Company has 51.39% insider ownership. RedHill Biopharma Ltd. (NASDAQ:RDHL) quarterly performance is 13.67% while its year to date ...and more »
05/31/16 07:00 AMRedHill Biopharma to Present at the 2016 BIO International Convention - [GlobeNewswire] - TEL-AVIV, Israel, May 31, 2016-- RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small ...
05/30/16 05:59 PMNext Weeks Broker Price Targets For Redhill Biopharma Ltd. (RDHL) - Share Trading News - Next Weeks Broker Price Targets For Redhill Biopharma Ltd. (RDHL)Share Trading NewsRedhill Biopharma Ltd. has a 50 day moving average of 12.12 and a 200 day moving average of 11.51. The stock's market capitalization is 140.09M, it has a 52-week low of 8.10 and a 52-week high of 22.22. The share price of the company (RDHL) was up ...Redhill Biopharma Limited Ads (NASDAQ:RDHL) Sellers Increased By 1.4% Their ShortsFranklin IndependentRedHill Biopharma to Present at Jefferies 2016 Healthcare ConferenceGlobeNewswire (press release)all 3 news articles »
05/30/16 08:00 AMRedHill Biopharma to Present at Jefferies 2016 Healthcare Conference - [GlobeNewswire] - TEL-AVIV, Israel, May 30, 2016-- RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small ...
05/25/16 01:56 PMBroker Roundup For Redhill Biopharma Ltd. (RDHL) - Share Trading News - Broker Roundup For Redhill Biopharma Ltd. (RDHL)Share Trading News05/06/2015 – Redhill Biopharma Ltd. was upgraded to “buy” by analysts at Zacks. They now have a USD 16 price target on the stock. The share price of Redhill Biopharma Ltd. (RDHL) was up +1.01% during the last trading session, with a day high of 10.99.and more »
05/21/16 01:40 PMAnalyst Rating Check on Redhill Biopharma Ltd. (NASDAQ:RDHL) - Wall Street Hints and News - Analyst Rating Check on Redhill Biopharma Ltd. (NASDAQ:RDHL)Wall Street Hints and NewsCurrently, sell-side analysts have provided a consensus stock rating of 1.25 on shares of Redhill Biopharma Ltd. (NASDAQ:RDHL). Analysts that cover the company will usually offer Buy, Sell, or Hold recommendations based on in-depth research.and more »
05/19/16 01:41 PMShare Performance and Target Price Review for Redhill Biopharma Ltd. (NASDAQ:RDHL) - Wall Street Hints and News - Share Performance and Target Price Review for Redhill Biopharma Ltd. (NASDAQ:RDHL)Wall Street Hints and NewsLooking at stock activity from multiple angles may be of benefit when examining share performance. Investors have the ability to focus in on short or long term share performance. During the most recent trading session, Redhill Biopharma Ltd.and more »
05/13/16 08:26 AMConsensus Rating Review for Redhill Biopharma Ltd. (NASDAQ:RDHL) - Wall Street Hints and News - Consensus Rating Review for Redhill Biopharma Ltd. (NASDAQ:RDHL)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1.25 on shares of Redhill Biopharma Ltd. (NASDAQ:RDHL). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell ...and more »
05/13/16 08:26 AMPerformance Recap and Target Perspective on Redhill Biopharma Ltd. (NASDAQ:RDHL) - Wall Street Hints and News - Performance Recap and Target Perspective on Redhill Biopharma Ltd. (NASDAQ:RDHL)Wall Street Hints and NewsIn the latest trading session, shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) moved -6.47%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a recent check ...and more »
05/08/16 07:38 AMRedhill Biopharma Limited Ads (NASDAQ:RDHL) Sellers Covered 9.07% of Their Shorts - B.O.D.Y Confidential - Redhill Biopharma Limited Ads (NASDAQ:RDHL) Sellers Covered 9.07% of Their ShortsB.O.D.Y ConfidentialThe stock of Redhill Biopharma Limited Ads (NASDAQ:RDHL) registered a decrease of 9.07% in short interest. RDHL's total short interest was 75,200 shares in May as published by FINRA. Its down 9.07% from 82,700 shares, reported previously. With 25,200 ...
05/06/16 08:15 AMAverage Analyst Rating for Redhill Biopharma Ltd. (NASDAQ:RDHL) - B.O.D.Y Confidential - Average Analyst Rating for Redhill Biopharma Ltd. (NASDAQ:RDHL)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1.25 on Redhill Biopharma Ltd. (NASDAQ:RDHL) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/04/16 07:00 AMRedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA™ Phase II Hepatocellular Carcinoma Study - [GlobeNewswire] - National Cancer Institute grant, awarded to the Medical University of South Carolina, is intended to support a research program covering a variety of solid tumor cancers, including a Phase II study with ...
05/02/16 08:40 AMRedhill Biopharma Ltd. (RDHL) Broker Price Targets For The Coming Week - Share Trading News - Redhill Biopharma Ltd. (RDHL) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Redhill Biopharma Ltd. (RDHL). The latest reports which are currently in issue on Monday 2nd of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...
04/30/16 08:09 AMShare Performance and Target Price Review Redhill Biopharma Ltd. (NASDAQ:RDHL) - B.O.D.Y Confidential - Share Performance and Target Price Review Redhill Biopharma Ltd. (NASDAQ:RDHL)B.O.D.Y ConfidentialDuring the most recent trading session, shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) ended up with a move of +3.2124%. Sell-side analysts have given a consensus target price of $29.7500 on company shares. Target price projections may differ greatly ...and more »
04/29/16 08:50 AMRedhill Biopharma Ltd. (NASDAQ:RDHL) Share Rating Recap - B.O.D.Y Confidential - Redhill Biopharma Ltd. (NASDAQ:RDHL) Share Rating RecapB.O.D.Y ConfidentialShares of Redhill Biopharma Ltd. (NASDAQ:RDHL) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from ...Redhill Biopharma Ltd. (NASDAQ:RDHL) Analyst Rating ReviewThe Postall 256 news articles »
04/28/16 08:20 AMRedhill Biopharma Ltd. (NASDAQ:RDHL) Analyst Rating Review - The Post - Redhill Biopharma Ltd. (NASDAQ:RDHL) Analyst Rating ReviewThe PostCurrently, there are 4 analysts that have provided ratings for Redhill Biopharma Ltd. (NASDAQ:RDHL). 3 have rated the stock a “Strong Buy”, 1 rate it a “Buy”, 0 are putting a Hold rating on the stock, and 0 are recommending “Sell”. Every recommendation ...and more »
04/27/16 09:44 AMLatest Analyst Ratings For Redhill Biopharma Ltd. (RDHL) - Share Trading News - Latest Analyst Ratings For Redhill Biopharma Ltd. (RDHL)Share Trading NewsRedhill Biopharma Ltd. has a 50 day moving average of 12.30 and a 200 day moving average of 11.58. It has a 52-week low of 8.10 and a 52-week high of 22.22. The share price of the company (RDHL) was down -1.99%, with a high of 13.08 during the day ...Zacks Investment Research Downgrades RedHill Biopharma Ltd - (RDHL) to SellWeb Breaking Newsall 4 news articles »
04/25/16 07:00 AMRedHill Biopharma to Present at BioNetwork East 2016 Partnering Summit - [GlobeNewswire] - TEL-AVIV, Israel, April 25, 2016-- RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, ...
04/22/16 09:13 AMQ1 Results: RedHill Biopharma Ltd (RDHL) - share market updates (press release) - Q1 Results: RedHill Biopharma Ltd (RDHL)share market updates (press release)Shares of RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) ended Thursday session in red amid volatile trading. The shares closed down -0.35 points or -2.61% at $13.06 with 17,557.00 million shares getting traded. Post opening the session at $13.42, the ...
04/20/16 06:45 AMRedHill Biopharma Reports 2016 First Quarter Financial Results - [GlobeNewswire] - RedHill maintains a strong and debt-free balance sheet with approximately $53 million in cash at the end of the first quarter, allowing the Company to continue to diligently execute its strategic and operational ...
04/19/16 09:40 AMWere Analysts Bearish RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) This Week? - Clinton Financial - Were Analysts Bearish RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) This Week?Clinton FinancialOut of 5 analysts covering RedHill Biopharma (NASDAQ:RDHL), 0 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. RedHill Biopharma was the topic in 7 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Below is a ...RedHill Biopharma to Participate in the FBR Co. Healthcare Series Focused on Infectious DiseasesEconoTimesRedhill Biopharma Adds More Than 2.5%, Says FDA Meeting Clears RHB-105 Path to Approval (NASDAQ:RDHL)Sonoran Weekly Reviewall 4 news articles »
04/19/16 05:05 AMRedHill Biopharma to Participate in the FBR & Co. Healthcare Series Focused on Infectious Diseases - [GlobeNewswire] - TEL-AVIV, Israel, April 19, 2016-- RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small ...
04/18/16 09:19 AMRedHill Biopharma Reports Results of FDA Meeting on RHB-105 Path to Approval, Planned Confirmation of Phase III ... - Benzinga - RedHill Biopharma Reports Results of FDA Meeting on RHB-105 Path to Approval, Planned Confirmation of Phase III ...BenzingaRedHill Biopharma Ltd. RDHL (TASE:RDHL) ("RedHill" or the "Company"), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory ...and more »
04/18/16 07:04 AM8:04 am RedHill Biopharma announces the conclusion of 'positive' Type B Meeting with the FDA regarding the path to marketing approval of RHB-105 & the planned confirmatory Phase III study -
04/18/16 07:00 AMRedHill Biopharma Announces Positive FDA Meeting on RHB-105 Path to Approval and Planned Confirmatory Phase III Study for H. pylori Infection - [GlobeNewswire] - The FDA has confirmed, subject to final minutes of the meeting, the planned two-arm, randomized, double-blind, active comparator design of the confirmatory Phase III study with RHB-105 for the treatment ...
04/14/16 01:35 PMAnalysts Offer Insights on Healthcare Companies: RedHill Biopharma Ltd (NASDAQ: RDHL), Oramed Pharmaceuticals ... - Markets.co - Analysts Offer Insights on Healthcare Companies: RedHill Biopharma Ltd (NASDAQ: RDHL), Oramed Pharmaceuticals ...Markets.coFBR Capital analyst Vernon Bernardino reiterated a Buy rating on RedHill Biopharma (NASDAQ: RDHL) today and set a price target of $33. The company's shares closed yesterday at $12.02. Bernardino noted, “RedHill Biopharma (RDHL) continues its strong ...
04/14/16 01:35 PMRedhill Biopharma Ltd. (NASDAQ:RDHL) Analyst Recommendation Outlook - Clinton Financial - Redhill Biopharma Ltd. (NASDAQ:RDHL) Analyst Recommendation OutlookClinton FinancialCovering analysts usually give Buy, Sell and Hold recommendations along with guidance and company earnings estimates. There are 4 analysts providing ratings for Redhill Biopharma Ltd. (NASDAQ:RDHL). 3 have given the stock a “Strong Buy”, 1 rate it a ...and more »
04/14/16 01:35 PMRedHill Biopharma Ltd – (RDHL) Rating Reiterated by FBR & Co. - Washington News Wire - Washington News WireRedHill Biopharma Ltd – (RDHL) Rating Reiterated by FBR & Co.Washington News WireRedHill Biopharma Ltd - logo RedHill Biopharma Ltd – (NASDAQ:RDHL)'s stock had its “buy” rating reissued by FBR & Co. in a research note issued to investors on Wednesday, MarketBeat.com reports. Several other equities analysts have also commented ...RedHill Biopharma to Host First Quarter 2016 Financial Results Conference Call on April 20, 2016EconoTimesRedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndromeNews-Medical.netall 5 news articles »
04/13/16 07:00 AMRedHill Biopharma to Host First Quarter 2016 Financial Results Conference Call on April 20, 2016 - [GlobeNewswire] - TEL-AVIV, Israel, April 13, 2016-- RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small ...
04/12/16 12:10 PMRedHill Biopharma (RDHL) Initiates Phase II Study of BEKINDA for Treatment of IBS-D - StreetInsider.com - RedHill Biopharma (RDHL) Initiates Phase II Study of BEKINDA for Treatment of IBS-DStreetInsider.comRedHill Biopharma Ltd. (NASDAQ: RDHL) today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant ...RedHill Biopharma Starts Phase II Study on Irritable Bowel Syndrome Treatment BEKINDA – Shares Up 1% (NASDAQ ...Sonoran Weekly Reviewall 3 news articles »
04/12/16 12:10 PMEarnings Watch on Redhill Biopharma Ltd. (NASDAQ:RDHL) - RiversideGazette.com - Earnings Watch on Redhill Biopharma Ltd. (NASDAQ:RDHL)RiversideGazette.comRedhill Biopharma Ltd. (NASDAQ:RDHL) has a consensus earnings per share estimate for the current quarter of $-0.49 based on compiled analyst projections. The company is next expected to release earnings on or around 2016-05-05 for the period ending ...
04/12/16 12:10 PMBroker Outlook For The Week Ahead Redhill Biopharma Ltd. (RDHL) - Share Trading News - Broker Outlook For The Week Ahead Redhill Biopharma Ltd. (RDHL)Share Trading NewsRecently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Redhill Biopharma Ltd. (RDHL). The most recent broker reports which have been released note that 1 analyst has a ...and more »
About RedHill Biopharma Ltd -

RedHill Biopharma Ltd - logoRedHill Biopharma Ltd. is a biopharmaceutical company primarily focused on the development of late clinical-stage, orally-administered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers. The Company's pipeline of products includes RHB-105, RHB-104, BEKINDA (RHB-102), RHB-106, ABC294640, MESUPRON, RP101 and RIZAPORT (RHB-103).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RDHL
  • CUSIP:
Key Metrics:
  • Previous Close: $10.59
  • 50 Day Moving Average: $10.93
  • 200 Day Moving Average: $11.20
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $134.62M
  • Current Quarter EPS Consensus Estimate: $-1.85 EPS
Additional Links:
RedHill Biopharma Ltd - (NASDAQ:RDHL) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha